MSD (Merck & Co.) has secured non-exclusive global rights to Cyprumed's oral peptide delivery platform, potentially transforming injectable peptide treatments into convenient tablet formulations.
UCB's Bimzelx Navigate program offers bridge access to therapy at $15 per dose for up to 2 years, addressing insurance coverage delays for commercially insured patients.